Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28416472 | 0.96 | LMNA (0.45) | LMNAHSD17B10GAAHPSEPDE4B | |
| SCHEMBL28411151 | 0.93 | LMNA (0.38) | LMNAHSD17B10GAAHPSEPDE4B | |
| SCHEMBL8611205 | 0.82 | LMNA (0.42) | LMNAHSD17B10GAAPDE4BPDE4D | |
| SCHEMBL2364931 | 0.81 | LMNA (0.41) | LMNAHSD17B10GAAPDE4BPDE4D | |
| SCHEMBL28415816 | 0.81 | HPSE (0.35) | LMNAHPSE | |
| SCHEMBL29045207 | 0.81 | HPSE (0.35) | LMNAHPSEPDE4BPDE4D | |
| SCHEMBL27700737 | 0.79 | LMNA (0.40) | LMNAHSD17B10GAAPDE4BPDE4D | |
| SCHEMBL30554033 | 0.77 | ALDH1A1 (0.40) | LMNAHSD17B10GAANPC1ALDH1A1 | |
| SCHEMBL30554006 | 0.73 | ALDH1A1 (0.43) | LMNAGAATHRBNPC1ALDH1A1 | |
| SCHEMBL18250732 | 0.69 | F10 (0.37) | LMNATHRBTP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111187218-B | Application of 1-substituted-1H-imidazole-2-carboxylic acid compound in preparation of metal beta-lactamase inhibitor | 四川大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-111253317-B | 1-substituted-1H-imidazole-2-carboxylic acid compound | 四川大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-111253317-A | 1-substituted-1H-imidazole-2-carboxylic acid compound | 四川大学 | 2020-06-09 | — | — | CN | disclosed |
| CN-111187218-A | Application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal β -lactamase inhibitor | 四川大学 | 2020-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | LMNA 1423/4885HSD17B10 2038/4885GAA 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.